Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,220,488 papers from all fields of science
Search
Sign In
Create Free Account
KI 3315
Known as:
KI-3315
, Ki3315
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Pyridines
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1994
1994
Comparative analysis of vasodilating mechanisms of Ki1769, Ki3315 and KRN2391, pyridinecarboximidamide derivatives, in porcine isolated coronary artery.
T. Yokoyama
,
Y. Okada
,
Y. Jinno
,
H. Izumi
,
T. Izawa
,
N. Ogawa
General Pharmacology
1994
Corpus ID: 4909149
1993
1993
Vasorelaxant action of Ki1769, a new pyridinecarboximidamide, in isolated porcine coronary artery.
Y. Okada
,
T. Yokoyama
,
+4 authors
N. Ogawa
European Journal of Pharmacology
1993
Corpus ID: 4533883
1993
1993
Effects of KRN2391, a novel vasodilator, on pancreatic exocrine secretion in anesthetized dogs.
K. Iwatsuki
,
A. Horiuchi
,
L. Ren
,
S. Chiba
European Journal of Pharmacology
1993
Corpus ID: 4526940
1993
1993
In vitro and in vivo K channel-opening effects of Ki3315, a metabolite of the novel vasodilator KRN2391.
Y. Tanaka
,
Y. Okada
,
+4 authors
N. Ogawa
Archives internationales de pharmacodynamie et de…
1993
Corpus ID: 22019621
The vasodilating potencies and mechanism of action of KRN2391 [N-cyano-N'-(2-nitroxyethyl)-3-pyridinecarboximidamide…
Expand
1992
1992
Vasodilating properties of KRN2391: structural basis of a new pyridine-type potassium channel opener with a nitrate moiety
T. Ishibashi
,
M. Hamaguchi
,
S. Imai
Naunyn-Schmiedeberg's Archives of Pharmacology
1992
Corpus ID: 6908154
SummaryThe vasodilating mechanism of a new compound, cyanoimino-3-pyridylmethylaminoethyl nitrate methanesulfonate (KRN2391), a…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE